Regeneron Pharmaceuticals said Monday it will pay $800 million to Alnylam, a biotechnology firm in Cambridge, Mass., to leverage its gene-silencing technique for the development of new therapies and to become its exclusive partner for new drugs focused on the central nervous system or the eye.

“It’s about the future, and it’s about synergies,” George Yancopoulos, Regeneron’s chief scientific officer and co-founder, said in an interview. “We’re not going to be making the standard deals where companies are just hoping to acquire an asset. We’re going to do the opposite. We’re looking for people with which we can do greater things together.”

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy